Serum Calcium to Phosphorous Ratio (Ca/P) as a Simple, Inexpensive Screening Tool in the Diagnosis of Primary Hyperparathyroidism

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03027349

Enrollment

180

Registered

2017-01-23

Start date

2011-01-31

Completion date

2017-02-28

Last updated

2017-02-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperparathyroidism

Brief summary

Background: Primary hyperparathyroidism (PHPT) is often overlooked and underdiagnosed. At present the diagnosis of PHPT remains challenging and is based on serum calcium (Ca) and PTH. As serum Ca and phosphorous (P) are inversely related in PHPT, the Ca/P ratio might be considered a good candidate tool in the diagnosis of PHPT. AIM: The aim of this study is to investigate the diagnostic value of the Ca/P ratio in the diagnosis of PHPT. Study design: Retrospective, observational, cross-sectional, case-control clinical trial will be carried out. Biochemical measurements will include PTH, Vitamin D, serum Ca, P, albumin, and creatinine.

Interventions

OTHERNo intervention are provided

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 90 Years

Healthy volunteers

Inclusion criteria

* elevated parathormone serum levels * normal or elevated calcium serum levels

Exclusion criteria

* age younger than 18 years * renal and liver failure and insufficiency * active metabolic bone disease (such as Paget's disease of the bone, osteomalacia, rickets, etc) * any type of cancer * malnutrition, severe obesity (BMI \> 40 kg/m2) and malabsorption * transplantation * sarcoidosis * endocrinological disorders such as hypercortisolism, diabetes insipidus, hyperthyroidism, pseudohypoparathyroidism * familial hypocalciuric hypercalcemia * hypophosphoremia sustained by genetic causes or secondary to other causes.

Design outcomes

Primary

Measure	Time frame	Description
Calcium	Enrollment time	Assay performed at the moment of diagnosis

Secondary

Measure	Time frame	Description
Phosphorus	Enrollment time	Assay performed at the moment of diagnosis
Parathormone	Enrollment time	Assay performed at the moment of diagnosis
Creatinine	Enrollment time	Assay performed at the moment of diagnosis
Albumine	Enrollment time	Assay performed at the moment of diagnosis
Vitamin D	Enrollment time	Assay performed at the moment of diagnosis

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026